

## **R-PPI TABLETS**

*Issue VIII, No. 30, 2023* 

Rabeprazole Co-administration Controls Ulcer Recurrence in Patients on Low-dose Aspirin Therapy: A Multicenter Prospective Study

Kinoshita Y et al. Intern Med 2023; 62(4): 495-502.

- Low-dose aspirin (LDA) can lead to GI mucosal injury, primarily by inhibiting the synthesis of endogenous prostaglandins.
- A large scale, multicenter, observational study was carried out between 2015-2018 to assess the rabeprazole co-administration (5/10 mg) in combination with LDA.
- It was observed that the incidence of adverse reactions was 0.73% (11/1513 patients) with no serious adverse reactions.
- The cumulative recurrence rate of ulcers by week 52 was 3.5% with no reports of GI bleeding.

Rabeprazole in combination with LDA appears as safe and effective in real world situations as in clinical trials.

\* \* \* \* \*